New insights into endocannabinoid degradation and its therapeutic potential

M. Bari, N. Battista, F. Fezza, V. Gasperi, M. Maccarrone

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Endocannabinoids are amides, esters and ethers of long chain polyunsaturated fatty acids, which act as new lipidic mediators. Anandamide (N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol (2-AG) are the main endogenous agonists of cannabinoid receptors, able to mimic several pharmacological effects of (-)-Δ9-tetrahydrocannabinol (THC), the active principle of Cannabis sativa preparations like hashish and marijuana. The activity of AEA and 2-AG at their receptors is limited by cellular uptake through an anandamide membrane transporter (AMT), followed by intracellular degradation. A fatty acid amide hydrolase (FAAH) is the main AEA hydrolase, whereas a monoacylglycerol lipase (MAGL) is critical in degrading 2-AG. Here, we will review growing evidence that demonstrates that these hydrolases are pivotal regulators of the endogenous levels of AEA and 2-AG in vivo, overall suggesting that specific inhibitors of AMT, FAAH or MAGL may serve as attractive therapeutic targets for the treatment of human disorders. Recently, the N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD), which synthesizes AEA from N-arachidonoylphosphatidylethanolamine (NArPE), and the diacylglycerol lipase (DAGL), which generates 2-AG from diacylglycerol (DAG) substrates, have been characterized. The role of these synthetic routes in maintaining the endocannabinoid tone in vivo will be discussed. Finally, the effects of inhibitors of endocannabinoid degradation in animal models of human disease will be reviewed, with an emphasis on their ongoing applications in anxiety, cancer and neurodegenerative disorders.

Original languageEnglish
Pages (from-to)257-268
Number of pages12
JournalMini-Reviews in Medicinal Chemistry
Volume6
Issue number3
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Endocannabinoids
Degradation
Cannabis
Monoacylglycerol Lipases
Membrane Transport Proteins
Hydrolases
Cannabinoid Receptor Agonists
Therapeutics
Animal Disease Models
Phospholipase D
Dronabinol
Ethers
Lipoprotein Lipase
Diglycerides
Corrosion inhibitors
Anxiety Disorders
Unsaturated Fatty Acids
Amides
Neurodegenerative Diseases
Esters

Keywords

  • 2-arachidonoylglycerol
  • Anandamide
  • Fatty acid amide hydrolase
  • Human disease
  • Membrane transport
  • Therapy

ASJC Scopus subject areas

  • Chemistry(all)
  • Medicine (miscellaneous)
  • Pharmacology

Cite this

New insights into endocannabinoid degradation and its therapeutic potential. / Bari, M.; Battista, N.; Fezza, F.; Gasperi, V.; Maccarrone, M.

In: Mini-Reviews in Medicinal Chemistry, Vol. 6, No. 3, 03.2006, p. 257-268.

Research output: Contribution to journalArticle

Bari, M. ; Battista, N. ; Fezza, F. ; Gasperi, V. ; Maccarrone, M. / New insights into endocannabinoid degradation and its therapeutic potential. In: Mini-Reviews in Medicinal Chemistry. 2006 ; Vol. 6, No. 3. pp. 257-268.
@article{4a175cbc202c4b8f9cdc19a677f5ec23,
title = "New insights into endocannabinoid degradation and its therapeutic potential",
abstract = "Endocannabinoids are amides, esters and ethers of long chain polyunsaturated fatty acids, which act as new lipidic mediators. Anandamide (N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol (2-AG) are the main endogenous agonists of cannabinoid receptors, able to mimic several pharmacological effects of (-)-Δ9-tetrahydrocannabinol (THC), the active principle of Cannabis sativa preparations like hashish and marijuana. The activity of AEA and 2-AG at their receptors is limited by cellular uptake through an anandamide membrane transporter (AMT), followed by intracellular degradation. A fatty acid amide hydrolase (FAAH) is the main AEA hydrolase, whereas a monoacylglycerol lipase (MAGL) is critical in degrading 2-AG. Here, we will review growing evidence that demonstrates that these hydrolases are pivotal regulators of the endogenous levels of AEA and 2-AG in vivo, overall suggesting that specific inhibitors of AMT, FAAH or MAGL may serve as attractive therapeutic targets for the treatment of human disorders. Recently, the N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD), which synthesizes AEA from N-arachidonoylphosphatidylethanolamine (NArPE), and the diacylglycerol lipase (DAGL), which generates 2-AG from diacylglycerol (DAG) substrates, have been characterized. The role of these synthetic routes in maintaining the endocannabinoid tone in vivo will be discussed. Finally, the effects of inhibitors of endocannabinoid degradation in animal models of human disease will be reviewed, with an emphasis on their ongoing applications in anxiety, cancer and neurodegenerative disorders.",
keywords = "2-arachidonoylglycerol, Anandamide, Fatty acid amide hydrolase, Human disease, Membrane transport, Therapy",
author = "M. Bari and N. Battista and F. Fezza and V. Gasperi and M. Maccarrone",
year = "2006",
month = "3",
doi = "10.2174/138955706776073466",
language = "English",
volume = "6",
pages = "257--268",
journal = "Mini-Reviews in Medicinal Chemistry",
issn = "1389-5575",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - New insights into endocannabinoid degradation and its therapeutic potential

AU - Bari, M.

AU - Battista, N.

AU - Fezza, F.

AU - Gasperi, V.

AU - Maccarrone, M.

PY - 2006/3

Y1 - 2006/3

N2 - Endocannabinoids are amides, esters and ethers of long chain polyunsaturated fatty acids, which act as new lipidic mediators. Anandamide (N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol (2-AG) are the main endogenous agonists of cannabinoid receptors, able to mimic several pharmacological effects of (-)-Δ9-tetrahydrocannabinol (THC), the active principle of Cannabis sativa preparations like hashish and marijuana. The activity of AEA and 2-AG at their receptors is limited by cellular uptake through an anandamide membrane transporter (AMT), followed by intracellular degradation. A fatty acid amide hydrolase (FAAH) is the main AEA hydrolase, whereas a monoacylglycerol lipase (MAGL) is critical in degrading 2-AG. Here, we will review growing evidence that demonstrates that these hydrolases are pivotal regulators of the endogenous levels of AEA and 2-AG in vivo, overall suggesting that specific inhibitors of AMT, FAAH or MAGL may serve as attractive therapeutic targets for the treatment of human disorders. Recently, the N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD), which synthesizes AEA from N-arachidonoylphosphatidylethanolamine (NArPE), and the diacylglycerol lipase (DAGL), which generates 2-AG from diacylglycerol (DAG) substrates, have been characterized. The role of these synthetic routes in maintaining the endocannabinoid tone in vivo will be discussed. Finally, the effects of inhibitors of endocannabinoid degradation in animal models of human disease will be reviewed, with an emphasis on their ongoing applications in anxiety, cancer and neurodegenerative disorders.

AB - Endocannabinoids are amides, esters and ethers of long chain polyunsaturated fatty acids, which act as new lipidic mediators. Anandamide (N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol (2-AG) are the main endogenous agonists of cannabinoid receptors, able to mimic several pharmacological effects of (-)-Δ9-tetrahydrocannabinol (THC), the active principle of Cannabis sativa preparations like hashish and marijuana. The activity of AEA and 2-AG at their receptors is limited by cellular uptake through an anandamide membrane transporter (AMT), followed by intracellular degradation. A fatty acid amide hydrolase (FAAH) is the main AEA hydrolase, whereas a monoacylglycerol lipase (MAGL) is critical in degrading 2-AG. Here, we will review growing evidence that demonstrates that these hydrolases are pivotal regulators of the endogenous levels of AEA and 2-AG in vivo, overall suggesting that specific inhibitors of AMT, FAAH or MAGL may serve as attractive therapeutic targets for the treatment of human disorders. Recently, the N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD), which synthesizes AEA from N-arachidonoylphosphatidylethanolamine (NArPE), and the diacylglycerol lipase (DAGL), which generates 2-AG from diacylglycerol (DAG) substrates, have been characterized. The role of these synthetic routes in maintaining the endocannabinoid tone in vivo will be discussed. Finally, the effects of inhibitors of endocannabinoid degradation in animal models of human disease will be reviewed, with an emphasis on their ongoing applications in anxiety, cancer and neurodegenerative disorders.

KW - 2-arachidonoylglycerol

KW - Anandamide

KW - Fatty acid amide hydrolase

KW - Human disease

KW - Membrane transport

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33646068357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646068357&partnerID=8YFLogxK

U2 - 10.2174/138955706776073466

DO - 10.2174/138955706776073466

M3 - Article

VL - 6

SP - 257

EP - 268

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

SN - 1389-5575

IS - 3

ER -